1. Scrip
  2. >>Business

Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns

Stock Up By 38%

 
• By Ayisha Sharma

Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.  

needle going into vial of drug
Filter Needles Are Used To Withdraw Syfovre From Its Vial • Source: Shutterstock
Key Takeaways:
  • The 19-gauge filter needle was found to have internal structural variations and Apellis has discontinued its distribution.
  • There have been a total of eight confirmed cases of retinal vascutilis to date, meaning rates are in the 1-in-10,000 range.
  • Syfovre performance could bounce back in time for its Q3 earnings following the update.

     

The culprit behind the unexpected side effects of Apellis Pharmaceuticals, Inc

Last month, the American Society of Retinal Specialists (ASRS) issued a letter highlighting real-world cases of eye inflammation and six events of occlusive retinal vasculitis in patients treated with Syfovre

More from Business

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.